Docetaxel Injection

Docetaxel is a paclitaxel anti-tumor drug that exerts its anti-tumor effect by interfering with the microtubule network necessary for cell mitosis and interphase cell function. Docetaxel can bind to free tubulin, promote tubulin assembly into stable microtubules, and inhibit its depolymerization, resulting in the production of microtubule bundles that have lost their normal functions and the fixation of microtubules, thereby inhibiting cell mitosis. The binding of docetaxel to microtubules does not change the number of protofilaments. This is different from most spindle toxic drugs currently used in clinical practice.

Dominican Republic

This product is a light orange-yellow to orange-yellow clear liquid.

1. Docetaxel is suitable for the treatment of advanced or metastatic breast cancer after failure of previous chemotherapy. Unless it is clinically contraindicated, limited treatment should include anthracycline anticancer drugs. 2. Docetaxel is suitable for the treatment of advanced or metastatic non-small cell lung cancer after failure of chemotherapy based on cisplatin.

Docetaxel can only be used for intravenous infusion. All patients must take oral glucocorticoids, such as dexamethasone, before receiving docetaxel treatment. Take it one day before docetaxel infusion, 16 mg per day, for at least 3 days to prevent allergic reactions and fluid retention. The recommended dose of docetaxel is 70-75 mg/m2, intravenous infusion for one hour, once every three weeks. According to the calculated amount of medication for the patient, draw the required dose with a syringe, dilute it into 5% grape injection or 0.9% sodium chloride injection, shake it gently, mix it evenly, and the final concentration does not exceed 0.74 mg/m1.

1. Bone marrow suppression: Neutropenia is the most common adverse reaction and is usually severe (less than 500/mm3). It is reversible and does not accumulate. According to literature reports, fever and infection related to neutropenia occur. Anemia can be seen in most cases, and severe thrombocytopenia occurs in a few cases. 2. Allergic reactions: Severe allergic reactions may occur in some cases, characterized by hypotension and bronchospasm, requiring treatment interruption. The patient can return to normal after stopping the infusion and immediate treatment. Mild allergic reactions may also occur in some cases. Such as flushing, erythema with or without itching, chest tightness, back pain, dyspnea, drug fever or chills. 3. Skin reactions often manifest as erythema, mainly seen in the hands and feet, and may also occur in local rashes on the arms, face and chest, sometimes accompanied by itching. The rash may usually occur within one week after the infusion of docetaxel, but it may recover before the next infusion. Severe symptoms such as peeling after the rash rarely occur. Nail lesions may occur, characterized by pigmentation or lightening, sometimes with pain and nail loss. 4. Fluid retention includes edema, and rare cases of pleural effusion, ascites, pericardial effusion, increased capillary permeability, and weight gain have also been reported. After 4 cycles of treatment or a cumulative dose of 400 mg/m2, fluid retention occurs in the lower extremities and may develop into systemic edema, with a weight gain of 3 kg or more. Fluid retention gradually disappears after stopping docetaxel treatment. To reduce fluid retention, patients should be given prophylactic corticosteroids. 5. Gastrointestinal reactions such as nausea, vomiting, or diarrhea may occur. 6. Neurotoxicity has been reported in clinical trials. 7. Cardiovascular adverse reactions such as hypotension, sinus tachycardia, palpitations, pulmonary edema, and hypertension may occur. 8. Other adverse reactions include: hair loss, weakness, mucositis, joint and muscle pain, hypotension, and injection site reactions. 9. Some patients with normal liver function may experience elevated transaminase and bilirubin during treatment, and the relationship between this and docetaxel is not clear.

1. Patients with a history of severe allergy to docetaxel or Tween-80; 2. Patients with a white blood cell count less than 1500/mm3; 3. Patients with severe liver damage.

In vitro studies have shown that CYP3A4 inhibitors may interfere with the metabolism of this product, so extreme caution should be exercised when it is used simultaneously with such drugs (such as ketoazole, erythromycin, cyclosporine, etc.).

Store at 2~8℃ in a sealed container in a dark place.

2.0ml:80mg